Carboprost tromethamine

Suppliers

Names

[ Name ]:
Carboprost tromethamine

[Synonym ]:
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
(5Z,9α,11α,13E,15S)-9,11,15-Trihydroxy-15-methylprosta-5,13-dien-1-oic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)
(15S)-15-Methylprostaglandin F2a Tromethamine
(5Z,9α,11α,13E,15S)-9,11,15-Trihydroxy-15-methylprosta-5,13-dien-1-oic acid - 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
(5Z)-7-{(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl}hept-5-ensäure--2-amino-2-(hydroxymethyl)propan-1,3-diol(1:1)
Hemabate
Prostin/15M
acide (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-3-méthyloct-1-én-1-yl]cyclopentyl}hept-5-énoïque - 2-amino-2-(hydroxyméthyl)propane-1,3-diol (1:1)
Carboprost tromethamine salt
15(S)15-Methyl pgf2a Tromethamine Salt
Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9α,11α,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
(5Z,9a,11a,13E,15S)-9,11,15-Trihydroxy-15-methylprosta-5,13-dien-1-oic Acid compd. with 2-Amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
Carboprost trometamol
Carboprost tromethamine
U 32921E
(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl}hept-5-enoic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)

Chemical & Physical Properties

[ Density]:
1.153g/cm3

[ Boiling Point ]:
536.6ºC at 760 mmHg

[ Molecular Formula ]:
C₂₅H₄₇NO₈

[ Molecular Weight ]:
489.643

[ Flash Point ]:
292.4ºC

[ Exact Mass ]:
489.330170

[ PSA ]:
184.70000

[ LogP ]:
1.79410

[ Water Solubility ]:
Soluble in water.

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UK8026000

CAS REGISTRY NUMBER :: 58551-69-2

LAST UPDATED :: 198910

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C21-H36-O5.C4-H11-N-O3

MOLECULAR WEIGHT :: 489.73

WISWESSER LINE NOTATION :: L5TJ AQ B2U4VQ C1U1XQ5&1 DQ &Q1XZ1Q1Q

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25100 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APTRDI Advances in Prostaglandin and Thromboxane Research. (New York, NY) V.1-8, 1976-80. Volume(issue)/page/year: 4,157,1978

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 131 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APTRDI Advances in Prostaglandin and Thromboxane Research. (New York, NY) V.1-8, 1976-80. Volume(issue)/page/year: 4,157,1978 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 30 ug/kg

SEX/DURATION :: female 14 week(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - abortion

REFERENCE :: CCPTAY Contraception. (Geron-X, Inc., POB 1108, Los Altos, CA 94022) V.1- 1970- Volume(issue)/page/year: 11,533,1975

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 87 ug/kg

SEX/DURATION :: female 15-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

REFERENCE :: APTRDI Advances in Prostaglandin and Thromboxane Research. (New York, NY) V.1-8, 1976-80. Volume(issue)/page/year: 4,157,1978

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 87 ug/kg

SEX/DURATION :: female 15-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Maternal Effects - parturition Reproductive - Fertility - abortion Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: APTRDI Advances in Prostaglandin and Thromboxane Research. (New York, NY) V.1-8, 1976-80. Volume(issue)/page/year: 4,157,1978

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 6 mg/kg

SEX/DURATION :: male 3 day(s) pre-mating female 3 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

REFERENCE :: APTRDI Advances in Prostaglandin and Thromboxane Research. (New York, NY) V.1-8, 1976-80. Volume(issue)/page/year: 4,157,1978

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 300 ug/kg

SEX/DURATION :: female 9-11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: APTRDI Advances in Prostaglandin and Thromboxane Research. (New York, NY) V.1-8, 1976-80. Volume(issue)/page/year: 4,157,1978

Safety Information

[ RIDADR ]:
NONH for all modes of transport

Articles

[The use of prostaglandin F2alpha (Prostin 15M) for terminationof second trimester pregnancy].

Akush. Ginekol. (Sofiia.) 52(2) , 53-5, (2013)

The authors describe a case of terminating a second trimester pregnancy in 21 gestational weeks with use of Prostin 15 M. The patient come to the clinic in 21 gestational week with spontaneous rupture...

[Application of Pfizer drugs in the obstetrics and gynecology practice].

Akush. Ginekol. (Sofiia.) 48 Suppl 1 , 41-4, (2009)

[Some possibilities for application of Pfizer medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice].

Akush. Ginekol. (Sofiia.) 46 Suppl 2 , 57-60, (2007)

The authors make a clinical and pharmacological overview of the possibilities of application in the obstetrician practice of part of the medicines of the company Pfiser. Some of these medicines have n...